Active Ingredient History
Hydralazine is a direct-acting vasodilator that is used as an antihypertensive agent. Hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. Hydralazine is used for the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension (approved 1985)
Alzheimer Disease (Phase 3)
Arterial Occlusive Diseases (Phase 2)
Atherosclerosis (Phase 3)
Blood Pressure (Phase 2)
Breast Neoplasms (Phase 2)
Cardio-Renal Syndrome (Phase 3)
Cardiovascular Diseases (Phase 3)
Cerebral Hemorrhage (Phase 2)
Coronary Disease (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 2)
Heart Failure (Phase 4)
Hemodialysis, Home (Phase 4)
Hypercholesterolemia (Phase 3)
Hypertension (Phase 4)
Hypertension, Pregnancy-Induced (Phase 3)
Ischemic Stroke (Phase 3)
Lung Neoplasms (Phase 1)
Macular Degeneration (Phase 2/Phase 3)
Mitral Valve Insufficiency (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 3)
Peripheral Nervous System Diseases (Phase 2/Phase 3)
Polycystic Kidney Diseases (Phase 3)
Pre-Eclampsia (Phase 2/Phase 3)
Rectal Neoplasms (Phase 1/Phase 2)
Shock, Cardiogenic (Phase 4)
Stroke (Phase 2)
Thrombosis (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Vascular Diseases (Phase 2)
Ventricular Dysfunction, Left (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
